{
    "Trade/Device Name(s)": [
        "Lumipulse\u00ae G ROMA\u00ae"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K160090",
    "Predicate Device Reference 510(k) Number(s)": [
        "K103358"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ONX"
    ],
    "Summary Letter Date": "April 14, 2016",
    "Summary Letter Received Date": "April 15, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6050"
    ],
    "Regulation Name(s)": [
        "Ovarian adnexal mass assessment score test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular",
        "chemistry"
    ],
    "Analyte(s)": [
        "HE4",
        "CA125"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "Dipotassium EDTA tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LUMIPULSE G1200 System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent enzyme immunoassay (CLEIA)",
        "Software algorithm"
    ],
    "Methodologies": [
        "Two-step sandwich immunoassay",
        "Risk of Ovarian Malignancy Algorithm (ROMA) calculation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Algorithm",
        "Calculator Tool",
        "Reagent",
        "Calibrator",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for Lumipulse G ROMA qualitative serum/plasma test combining HE4, CA125, and menopausal status to assess ovarian malignancy risk using CLEIA on LUMIPULSE G1200",
    "Indications for Use Summary": "Aids in assessing whether a premenopausal or postmenopausal woman presenting with an ovarian adnexal mass planned for surgery (not yet referred to oncologist, age >18) is at high or low likelihood of finding malignancy, based on serum/plasma HE4 and CA125 levels plus menopausal status; not for screening or stand-alone diagnosis, and must be interpreted with independent clinical/radiological assessment",
    "fda_folder": "Obstetrics"
}